Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: J Pharmacokinet Pharmacodyn. 2020 Apr 22;47(3):199–218. doi: 10.1007/s10928-020-09684-2

Table 3.

Type-I-error for the NPDE-based model evaluation approach (positive-control simulation study)

Number of Subjects Samples per Subject Total Samples Iterationsa P-value (μNPDE)b P-value (NPC)c
5 3 15 467 0.028 0.61
10 3 30 491 0.047 0.894
20 3 60 498 0.042 1
30 3 90 500 0.06 1
5 6 30 493 0.053 0.85
10 6 60 496 0.026 0.974
20 6 120 498 0.038 0.998
30 6 180 497 0.038 1
5 9 45 492 0.03 0.868
10 9 90 497 0.054 0.988
20 9 180 499 0.036 1
30 9 270 499 0.056 1

μNPDE mean of normalized prediction distribution errors; NPC, numerical predictive check

a

Iterations (out of 500) where the standard deviation of NPDE were not optimized to within ±0.01 of the target value (i.e., 1) by the developed fitting algorithm were excluded from the analysis.

b

Type-I-error for the NPDE-based model evaluation approach. Computed as the proportion of iterations where the μNPDE was statistically different than 0 (p-value<0.05; two-sided Student’s t-test).

c

Type-I-error for the conventional evaluation approach. Computed as the proportion of iterations where the proportion of observed data exceeding the model’s 90% prediction interval was statistically > 0.10 (p-value < 0.05; exact binomial test)